Cadrenal Therapeutics, Inc.
No enriched coverage for $CVKD in the last 7 days.
No SEC Form 4 filings for $CVKD in the last 30 days.
See all $CVKD insider activity →U.S. stock futures eased after a strong H1 rally, with Dow up about 8.9%, S&P 500 up 9.6%, Nasdaq up 12.8%, and Russell 2000 up about 22%. Traders look ahead to ADP and Thursday’s nonfarm payrolls for Fed signals. Several stocks moved premarket: NKE -4%, TSLA deliveries ~410k expected, NIO -4%, MU -4%, LUNR +8%, ASTS +20%, CVKD -16%.
Cadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030204201ex99-1.htm PRESS RELEASE, ISSUED BY CADRENAL THERAPEUTICS, INC. ON AUGUST 13, 2026 Exhibit 99.1 Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Par
Cadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029808201ex10-1.htm CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE, DATED AS OF JULY 9, 2026, BY AND BETWEEN CADRENAL THERAPEUTICS, INC. AND JAMES J. FERGUSON III Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE This Confidential Separation Ag
Recent CVKD coverage spans corporate actions, insider activity and market movers.
Dilutive capital raise likely pressures valuation and increases near-term supply overhang risk.
Near-term trading focus is financing runway and partner-likelihood for CAD-1005, alongside incremental clinical/regulatory signals.
This is an executive departure with severance and benefits terms, which can affect near-term leadership stability and internal execution risk.
The Phase 2 efficacy and safety signals for CAD-1005 are a meaningful catalyst for CVKD’s clinical narrative and Phase 3 readiness.
Board-level medical leadership change can affect clinical execution and investor sentiment, but the filing provides no clinical or financial updates.
alphai scores every news story that mentions CVKD with an AI model for sentiment and relevance, and aggregates insider trades from Cadrenal Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
U.S. stock futures eased after a strong H1 rally, with Dow up about 8.9%, S&P 500 up 9.6%, Nasdaq up 12.8%, and Russell 2000 up about 22%. Traders look ahead to ADP and Thursday’s nonfarm payrolls for Fed signals. Several stocks moved premarket: NKE -4%, TSLA deliveries ~410k expected, NIO -4%, MU -4%, LUNR +8%, ASTS +20%, CVKD -16%.
4 min readCadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030204201ex99-1.htm PRESS RELEASE, ISSUED BY CADRENAL THERAPEUTICS, INC. ON AUGUST 13, 2026 Exhibit 99.1 Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Par
6 min readCadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029808201ex10-1.htm CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE, DATED AS OF JULY 9, 2026, BY AND BETWEEN CADRENAL THERAPEUTICS, INC. AND JAMES J. FERGUSON III Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE This Confidential Separation Ag
2 min readCadrenal Therapeutics (Nasdaq: CVKD) said Phase 2 late-breaking data for its 12-LOX inhibitor CAD-1005 were presented at ISTH 2026. In HIT, CAD-1005 showed an absolute reduction of more than 25% in new or worsening thrombotic events vs placebo (50% vs >75%) and no CAD-1005-attributable serious adverse events or deaths. Company cites $2B peak annual revenue potential.
4 min readCadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001937993 0001937993 2026-07-07 2026-07-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readCadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ea029666601ex10-1.htm FORM OF SECURITIES PURCHASE AGREEMENT, DATED JUNE 30, 2026, BY AND BETWEEN CADRENAL THERAPEUTICS, INC. AND THE PURCHASER NAMED THEREIN Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of
4 min readCadrenal Therapeutics, Inc. (CVKD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ea029632801ex10-1.htm MASTER SERVICES AGREEMENT, DATED AUGUST 21, 2024, BETWEEN THE COMPANY AND LOHMAN & ASSOCIATES, INC Exhibit 10.1 MASTER SERVICES AGREEMENT This Master Services Agreement (this “ Agreement ”) is entered into as of August 21, 2024 (the “ Effective Dat
3 min readCadrenal Therapeutics said it plans to file for FDA Rare Pediatric Disease designation for tecarfarin in children with Kawasaki disease who develop coronary artery aneurysms. The company says tecarfarin is designed to provide more stable anticoagulation than warfarin. If approved, Cadrenal could receive a Priority Review Voucher, which it notes has sold for $180M–$205M.
5 min readPham Quang X (CEO and Chairman) sold 2,064 shares of Cadrenal Therapeutics, Inc. (CVKD) at $4.42 on 2026-06-05 under a Rule 10b5-1 trading plan.
2 min readPham Quang X (CEO and Chairman) sold 3,898 shares of Cadrenal Therapeutics, Inc. (CVKD) at $4.41 on 2026-06-04 under a Rule 10b5-1 trading plan.
2 min read
